A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China – CNBC

Posted on by
  1. A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China  CNBC
  2. Lung Cancer Patients on Drug From China’s Akeso Lived Longer  Bloomberg.com
  3. Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer  statnews.com
  4. ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%  Fierce Pharma
  5. Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means  Endpoints News
Share
XLinkedInWhatsAppTelegramPinterestReddit

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *